Goh BC - Search Results

1

Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.

Syn NL, Yong WP, Goh BC, Lee SC. Syn NL, et al. Among authors: goh bc. Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):911-22. doi: 10.1080/17425255.2016.1196187. Epub 2016 Jun 13. Expert Opin Drug Metab Toxicol. 2016. PMID: 27249175 Review.

2

Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer.

Goh BC, Lehnert M, Lim HL, Ng AW, Chan CC, Kong HL, Lee SC, Wee J, Chua ET, Wong JE. Goh BC, et al. Acta Oncol. 2000;39(2):225-9. doi: 10.1080/028418600430824. Acta Oncol. 2000. PMID: 10859016 Clinical Trial.

3

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.

Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS. Goh BC, et al. J Clin Oncol. 2002 Sep 1;20(17):3683-90. doi: 10.1200/JCO.2002.01.025. J Clin Oncol. 2002. PMID: 12202670

4

A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma.

Wang LZ, Goh BC, Grigg ME, Lee SC, Khoo YM, Lee HS. Wang LZ, et al. Among authors: goh bc. Rapid Commun Mass Spectrom. 2003;17(14):1548-52. doi: 10.1002/rcm.1091. Rapid Commun Mass Spectrom. 2003. PMID: 12845579

5

Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma.

Lee SC, Lim SG, Soo R, Hsieh WS, Guo JY, Putti T, Tao Q, Soong R, Goh BC. Lee SC, et al. Among authors: goh bc. Pharmacogenet Genomics. 2006 Jan;16(1):73-4. doi: 10.1097/01.fpc.0000184959.82903.02. Pharmacogenet Genomics. 2006. PMID: 16344724

6

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population.

Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, Guo JY, Yap HL, Rankin SC, Khor HB, Yeo TC, Ng KS, Soong R, Goh BC. Lee SC, et al. Among authors: goh bc. Clin Pharmacol Ther. 2006 Mar;79(3):197-205. doi: 10.1016/j.clpt.2005.11.006. Clin Pharmacol Ther. 2006. PMID: 16513444

7

Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.

Tham LS, Lee HS, Wang L, Yong WP, Fan L, Ong AB, Sukri N, Soo R, Lee SC, Goh BC. Tham LS, et al. Among authors: goh bc. Ther Drug Monit. 2006 Apr;28(2):255-61. doi: 10.1097/01.ftd.0000194497.55269.d9. Ther Drug Monit. 2006. PMID: 16628140 Clinical Trial.

8

A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.

Soo RA, Wang LZ, Tham LS, Yong WP, Boyer M, Lim HL, Lee HS, Millward M, Liang S, Beale P, Lee SC, Goh BC. Soo RA, et al. Among authors: goh bc. Ann Oncol. 2006 Jul;17(7):1128-33. doi: 10.1093/annonc/mdl084. Epub 2006 May 2. Ann Oncol. 2006. PMID: 16670205 Free article. Clinical Trial.

9

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, Lee SC. Tham LS, et al. Among authors: goh bc. Clin Pharmacol Ther. 2006 Oct;80(4):346-55. doi: 10.1016/j.clpt.2006.06.009. Clin Pharmacol Ther. 2006. PMID: 17015052

10

Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients.

Sandanaraj E, Jada SR, Shu X, Lim R, Lee SC, Zhou Q, Zhou S, Goh BC, Chowbay B. Sandanaraj E, et al. Among authors: goh bc. Pharmacogenomics J. 2008 Jun;8(3):174-85. doi: 10.1038/sj.tpj.6500473. Epub 2007 Aug 14. Pharmacogenomics J. 2008. PMID: 17700594

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

344 results

Search Page

Filters